IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishBackground: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.
Bianco, A., Mari, P. -., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L., Mirabella, M., Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2020; 37 (37): 101450-101453. [doi:10.1016/j.msard.2019.101450] [http://hdl.handle.net/10807/151231]
| Autori: | ||
| Titolo: | Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.msard.2019.101450 | |
| Data di pubblicazione: | 2020 | |
| Abstract: | Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Bianco, A., Mari, P. -., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L., Mirabella, M., Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2020; 37 (37): 101450-101453. [doi:10.1016/j.msard.2019.101450] [http://hdl.handle.net/10807/151231] | |
| Appare nelle tipologie: | Editoriale in rivista |
File in questo prodotto:
http://hdl.handle.net/10807/151231
Copyright © 2021